{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:00:08Z","timestamp":1790222408928,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.nmni.2025.101601","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T02:42:31Z","timestamp":1748400151000},"page":"101601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-4057","authenticated-orcid":false,"given":"Abolfazl Rafati","family":"Zomorodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Ghanbari_Afra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Faridafshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Nooreddin","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Zarepour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryamosadat","family":"Mavaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Rahmanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmni.2025.101601_bib1","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1038\/s41467-023-40494-5","article-title":"Profiling cell envelope-antibiotic interactions reveals vulnerabilities to \u03b2-lactams in a multidrug-resistant bacterium","volume":"14","author":"Hogan","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.nmni.2025.101601_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00590-18","article-title":"In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.nmni.2025.101601_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/mdr.2021.0353","article-title":"Susceptibility of Burkholderia cepacia complex to ceftazidime\/avibactam and standard drugs of treatment for cystic fibrosis patients","volume":"28","author":"Schaumburg","year":"2022","journal-title":"Microb Drug Resist"},{"issue":"1","key":"10.1016\/j.nmni.2025.101601_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12866-022-02738-0","article-title":"Phage-antibiotic synergy reduces Burkholderia cenocepacia population","volume":"23","author":"Mankovich","year":"2023","journal-title":"BMC Microbiol"},{"issue":"7","key":"10.1016\/j.nmni.2025.101601_bib5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","article-title":"Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients","volume":"3","author":"Papp-Wallace","year":"2017","journal-title":"ACS Infect Dis"},{"issue":"11","key":"10.1016\/j.nmni.2025.101601_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01332-21","article-title":"Activity of imipenem-relebactam against multidrug- and extensively drug-resistant Burkholderia cepacia complex and Burkholderia gladioli","volume":"65","author":"Becka","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.nmni.2025.101601_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00181-19","article-title":"\"Switching partners\": piperacillin-avibactam is a highly potent combination against multidrug-resistant Burkholderia cepacia complex and Burkholderia gladioli cystic fibrosis isolates","volume":"57","author":"Zeiser","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.nmni.2025.101601_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jac\/dky423","article-title":"In vitro activity of seven \u03b2-lactams including ceftolozane\/tazobactam and ceftazidime\/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients","volume":"74","author":"Massip","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.nmni.2025.101601_bib9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/jac\/dky558","article-title":"Use of ceftazidime\/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series","volume":"74","author":"Spoletini","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.nmni.2025.101601_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2021.102099","article-title":"New potentiators of ineffective antibiotics: targeting the Gram-negative outer membrane to overcome intrinsic resistance","volume":"66","author":"Klobucar","year":"2022","journal-title":"Curr Opin Chem Biol"},{"issue":"4","key":"10.1016\/j.nmni.2025.101601_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad091","article-title":"Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study","volume":"5","author":"Baltas","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.nmni.2025.101601_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.nmni.2025.101601_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-016-0142-3","article-title":"Effect of \u03b2-Lactamase inhibitors on in vitro activity of \u03b2-Lactam antibiotics against Burkholderia cepacia complex species","volume":"5","author":"Everaert","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"issue":"2","key":"10.1016\/j.nmni.2025.101601_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jac\/dky423","article-title":"In vitro activity of seven \u03b2-lactams including ceftolozane\/tazobactam and ceftazidime\/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients","volume":"74","author":"Massip","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.nmni.2025.101601_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01595-19","article-title":"In vitro activities of \u03b2-lactam\u2013\u03b2-lactamase inhibitor antimicrobial agents against cystic fibrosis respiratory pathogens","volume":"64","author":"Caverly","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.nmni.2025.101601_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00590-18","article-title":"In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.nmni.2025.101601_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/mdr.2021.0353","article-title":"Susceptibility of Burkholderia cepacia complex to ceftazidime\/avibactam and standard drugs of treatment for cystic fibrosis patients","volume":"28","author":"Schaumburg","year":"2022","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.nmni.2025.101601_bib18","series-title":"IN vitro activity of ceftazidime-avibactam against burkholderia cepacia complex (BCC) strains isolated from CF patients","year":"2018"},{"issue":"7","key":"10.1016\/j.nmni.2025.101601_bib19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","article-title":"Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients","volume":"3","author":"Papp-Wallace","year":"2017","journal-title":"ACS Infect Dis"},{"issue":"11","key":"10.1016\/j.nmni.2025.101601_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00498-23","article-title":"Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States","volume":"67","author":"Mojica","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2025.101601_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1151594","article-title":"Genomic features, antimicrobial susceptibility, and epidemiological insights into Burkholderia cenocepacia clonal complex 31 isolates from bloodstream infections in India","volume":"13","author":"Saroha","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.nmni.2025.101601_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jgar.2024.01.023","article-title":"In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis","volume":"36","author":"Tunney","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"11","key":"10.1016\/j.nmni.2025.101601_bib23","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+ NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.nmni.2025.101601_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrmicro1085","article-title":"The multifarious, multireplicon Burkholderia cepacia complex","volume":"3","author":"Mahenthiralingam","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.nmni.2025.101601_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s15010-018-1261-y","article-title":"Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime\u2013avibactam","volume":"47","author":"Los-Arcos","year":"2019","journal-title":"Infection"},{"issue":"11","key":"10.1016\/j.nmni.2025.101601_bib26","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.nmni.2025.101601_bib27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jinf.2018.07.006","article-title":"Burkholderia cepacia complex infections: more complex than the bacterium name suggest","volume":"77","author":"Sfeir","year":"2018","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.nmni.2025.101601_bib28","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/jac\/dky558","article-title":"Use of ceftazidime\/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series","volume":"74","author":"Spoletini","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.nmni.2025.101601_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1115877","article-title":"Burkholderia cepacia infection in children without cystic fibrosis: a clinical analysis of 50 cases","volume":"11","author":"Shi","year":"2023","journal-title":"Frontiers in Pediatrics"},{"key":"10.1016\/j.nmni.2025.101601_bib30","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s10096-020-03960-2","article-title":"Management and outcomes of Burkholderia cepacia complex bacteremia in patients without cystic fibrosis: a retrospective observational study","volume":"39","author":"Lee","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.nmni.2025.101601_bib31","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/cid\/cix559","article-title":"A 17-year nationwide study of Burkholderia cepacia complex bloodstream infections among patients in the United States Veterans Health Administration","volume":"65","author":"El Chakhtoura","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.nmni.2025.101601_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00498-23","article-title":"Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States","volume":"67","author":"Mojica","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.nmni.2025.101601_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00181-19","article-title":"\u201cSwitching partners\u201d: piperacillin-avibactam is a highly potent combination against multidrug-resistant Burkholderia cepacia complex and Burkholderia gladioli cystic fibrosis isolates","volume":"57","author":"Zeiser","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.nmni.2025.101601_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13082","article-title":"Successful ceftazidime\u2010avibactam treatment of post\u2010surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis","volume":"21","author":"Dacc\u00f2","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.nmni.2025.101601_bib35","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","article-title":"Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients","volume":"3","author":"Papp-Wallace","year":"2017","journal-title":"ACS Infect Dis"},{"issue":"11","key":"10.1016\/j.nmni.2025.101601_bib36","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.nmni.2025.101601_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02213-17","article-title":"Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam","volume":"62","author":"Tamma","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.nmni.2025.101601_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-17","article-title":"In vitro activity of ceftolozane-tazobactam and other antimicrobial agents against Burkholderia cepacia complex and Burkholderia gladioli","volume":"61","author":"Mazer","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.nmni.2025.101601_bib39","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.nmni.2025.101601_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drup.2016.07.003","article-title":"Antibiotic resistance in Burkholderia species","volume":"28","author":"Rhodes","year":"2016","journal-title":"Drug Resist Updates"},{"issue":"3","key":"10.1016\/j.nmni.2025.101601_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhin.2017.09.010","article-title":"Outbreak of Burkholderia cepacia bacteraemia in a tertiary care centre due to contaminated ultrasound probe gel","volume":"98","author":"Abdelfattah","year":"2018","journal-title":"J Hosp Infect"},{"issue":"5","key":"10.1016\/j.nmni.2025.101601_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1751-7915.2012.00334.x","article-title":"When it comes to drug discovery not all Gram-negative bacterial biodefence pathogens are created equal: Burkholderia pseudomallei is different","volume":"5","author":"Schweizer","year":"2012","journal-title":"Microb Biotechnol"},{"issue":"2","key":"10.1016\/j.nmni.2025.101601_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00592-20","article-title":"Burkholderia ubonensis meropenem resistance: insights into distinct properties of class A \u03b2-lactamases in Burkholderia cepacia complex and Burkholderia pseudomallei complex bacteria","volume":"11","author":"Somprasong","year":"2020","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.nmni.2025.101601_bib44","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1038\/s41467-023-40494-5","article-title":"Profiling cell envelope-antibiotic interactions reveals vulnerabilities to \u03b2-lactams in a multidrug-resistant bacterium","volume":"14","author":"Hogan","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.nmni.2025.101601_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01332-21","article-title":"Activity of imipenem-relebactam against multidrug-and extensively drug-resistant Burkholderia cepacia complex and Burkholderia gladioli","volume":"65","author":"Becka","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.nmni.2025.101601_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02534-16","article-title":"Mutations in bla(KPC-3) that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum \u03b2-lactamases","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.nmni.2025.101601_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla(KPC-3) mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.nmni.2025.101601_bib48","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of ceftazidime-avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.nmni.2025.101601_bib49","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3390\/antibiotics10080995","article-title":"Old and new beta-lactamase inhibitors: molecular structure, mechanism of action, and clinical Use","volume":"10","author":"Carcione","year":"2021","journal-title":"Antibiotics"},{"issue":"26","key":"10.1016\/j.nmni.2025.101601_bib50","doi-asserted-by":"crossref","first-page":"19090","DOI":"10.1074\/jbc.M113.458315","article-title":"Insights into \u03b2-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants","volume":"288","author":"Papp-Wallace","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.nmni.2025.101601_bib51","article-title":"In vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing enterobacterales","volume":"12","author":"Bonnin","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.nmni.2025.101601_bib52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1128\/AAC.00946-08","article-title":"Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex","volume":"53","author":"Poirel","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.nmni.2025.101601_bib53","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1128\/AAC.01068-15","article-title":"Cell wall recycling-linked coregulation of AmpC and PenB \u03b2-lactamases through ampD mutations in Burkholderia cenocepacia","volume":"59","author":"Hwang","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.nmni.2025.101601_bib54","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/jac\/dku237","article-title":"Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C \u03b2-lactamase enzyme","volume":"69","author":"Lahiri","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205229752500040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205229752500040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T20:20:11Z","timestamp":1754684411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205229752500040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":54,"alternative-id":["S205229752500040X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2025.101601","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2025.101601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101601"}}